BioGaia product effective in constipated adults
A study of 40 adults with constipation shows that the patients given Lactobacillus reuteri Protectis were significantly less constipated after four weeks compared to the patients given placebo.
In the double blind, placebo-controlled study 40 adults, diagnosed with functional constipation, were supplemented with either two chewable tablets per day of Lactobacillus reuteri Protectis or corresponding placebo. The intervention period was four weeks and constipation was measured as number of bowel movements per week. Bowel movements were recorded for each patient at the start of the study and after four weeks (end of study).
At the end of the study the group given Lactobacillus reuteri Protectis had significantly more bowel movements per week than the group given placebo. The results are the first with Lactobacillus reuteri Protectis in adult patients with functional constipation and confirm earlier positive data in children.
The results were published in J Gastrointestin Liver Dis on 9 December 2014. Study details are found through the attached link.
“Constipation is a common problem world wide and many of the current treatment options have side effects. Lactobacillus reuteri Protectis has already been shown to be an effective alternative in children and it is satisfying that the new results confirm that this also applies to adults with constipation”, says Peter Rothschild, President, BioGaia.
Latest press releases from BioGaia
2014-12-01 BioGaia invests in promising research company
2014-10-24 Infants with colic cry less with BioGaia’s drops
2014-10-22 BioGaia AB Interim management report 1 January – 30 September 2014
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 11 December 2014, 09:30 am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
Tags:
